Details of the Drug
General Information of Drug (ID: DMNX245)
| Drug Name | 
                     NSC-26745 
                 | 
            ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | 
                                         
                        5-Hydroxyflavone; 491-78-1; Primuletin; 5-hydroxy-2-phenyl-4H-chromen-4-one; 5-hydroxy-2-phenylchromen-4-one; NSC-26745; 5-Hydroxy-2-phenyl-chromen-4-one; NSC 26745; 5-Hydroxy-2-phenylchromone; UNII-378AE9MHL3; CHEMBL16807; MLS002639146; 378AE9MHL3; IYBLVRRCNVHZQJ-UHFFFAOYSA-N; NSC26745; MFCD00016944; 4H-1-Benzopyran-4-one,5-hydroxy-2-phenyl-; Primuliten; 5-hydroxy-flavone; 5-Hydroxy-2-phenyl-4-benzopyrone; EINECS 207-743-1; 5-hydroxy-2-phenyl-4h-chromen-4-on; AC1Q6AKC; ACMC-209kf5; Oprea1_688541; 5-Hydroxyflavone, >=97%
                        
                     
                                     | 
            ||||||||||||||||||||||
| Indication | 
                                                            
  | 
            ||||||||||||||||||||||
| Drug Type | 
                     Small molecular drug 
                 | 
            ||||||||||||||||||||||
| Structure | 
                    ![]()  | 
            ||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 238.24 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.5 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers | 
                        
  | 
                ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT)  | 
                
                    
  | 
            |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() Drug Off-Target (DOT)  | 
                
                    
  | 
            |||||||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
                    
  | 
            ||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References



